NIST

Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures

EAST HANOVER, N.J.--(BUSINESS WIRE)--Jul 11, 2007 - Since the May2007 release of a New England Journal of Medicine (NEJM) reportthat Avandia users are 43 percent more likely to suffer a heartattack and 67 percent more likely to die of cardiovascular causesthan non-users of Avandia, it is no surprise that physicians intendto switch many type 2 diabetes patients from Avandia to therapiesbelie...

New Proof of Genistein's Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Jun 27, 2007 - Annals ofInternal Medicine has published the results of a two-year clinicalstudy on the impact of genistein on bone loss. The paper, "Effectsof the Phytoestrogen Genistein on Bone Metabolism in OsteopenicPostmenopausal Women-A Randomized Trial," appears in the currentissue (June 19, 2007) and details the safety and efficacy ofgenistein for...

Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine

LIVINGSTON, N.J.--(BUSINESS WIRE)--Jun 27, 2007 - ColumbiaLaboratories, Inc. (NASDAQ: CBRX) today announced positive resultsfrom a recently-completed multi-dose pharmacokinetic study ofvaginally-administered lidocaine, which the Company is developingto prevent and treat dysmenorrhea. This 42-subject study was designed to provide data on bloodlevels associated with the Company's bioadhesiv...

Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis

RESEARCH TRIANGLE PARK, N.C. & SHERBROOKE, Quebec--(BUSINESSWIRE)--Jun 26, 2007 - Tranzyme Pharma, a leading biopharmaceuticalcompany developing small molecule drugs for the treatment ofgastrointestinal and metabolic diseases, today announced positiveresults for its novel ghrelin agonist, TZP-101, in acceleratinggastric emptying in diabetic patients with gastroparesis. The datafrom a pi...

Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Association's Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2007 - ElixirPharmaceuticals, Inc., today announced the presentation of two setsof preclinical data demonstrating that ghrelin antagonism may be apotential method for future treatment of a range of metabolicdisorders. These data demonstrated a variety of beneficialmetabolic effects, notably decreasing body weight, improvements inblood glucose and i...

Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration

PARIS--(BUSINESS WIRE)--Jun 11, 2007 - Regulatory News-Ipsen(Paris:IPN) announced today that the preliminary data from theongoing phase III study for its investigational 4-month formulationof triptorelin do not support the expected sustainable blood levelsof triptorelin for a duration of 4 months in all patients.Therefore, Ipsen has decided not to perform the secondadministration as planned...

Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection

Study Shows Safety and Pharmacokinetics Similar to IV Doses inPhase 3 CLL Trial BERKELEY HEIGHTS, N.J., June 06, 2007 /PRNewswire-FirstCall/ --Genta Incorporated announced the publication of preliminaryclinical results that show the Company's lead anti-cancer drug,Genasense(R) (oblimersen sodium) injection, can be safelyadministered by intermittent subcutaneous (SC) injection, as wellas...

Idera Pharmaceuticals Announces Presentations of Preclinical Data on New Potential Oncology Applications of its TLR9 Agonists at AACR

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - IderaPharmaceuticals, Inc. (AMEX: IDP) today announced two presentationsof data for two new potential applications in oncology of its novelagonists of Toll-like receptor 9 (TLR9) at the Annual Meeting ofthe American Association for Cancer Research (AACR) being held inLos Angeles, CA, April 14-18, 2007. The first presentation covereda preclin...

Curis Announces Hedgehog and Wnt Antagonist Data Presentation at AACR

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, 2007 - Curis, Inc.(NASDAQ:CRIS), a drug development company focused on novel targetedmedicines primarily for cancer treatment, today announced that itsdata was included in two presentations at the 98th Annual Meetingof the American Association for Cancer Research (AACR). At AACR, Curis also disclosed that its April 2005 discoverycollaboration agr...

AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles

JMR-132 could provide a new therapeutic approach for the treatmentof early and metastatic breast cancer QUEBEC CITY, April 17, 2007 /PRNewswire-FirstCall/ - AEternaZentaris Inc. , a global, pure play biopharmaceutical companyfocused on endocrine therapy and oncology, today presented anabstract outlining in vivo data for its growth hormone-releasinghormone (GHRH) antagonist JMR-132 in brea...

AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles

QUEBEC CITY, April 13, 2007 /PRNewswire-FirstCall/ - AEternaZentaris Inc. , a global, pure play biopharmaceutical companyfocused on endocrine therapy and oncology, today announced that itwill present two abstracts outlining first in vitro data on itsPI3K inhibitors as well as in vivo data on its GHRH antagonist,JMR-132, which both may potentially provide new therapeuticapproaches for the...

Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology

NEW ORLEANS, March 28, 2007 /PRNewswire/ -- PortolaPharmaceuticals, Inc. presented Phase I data of its ADP receptorantagonist at the of Cardiology's (ACC) 56th Annual ScientificSession this week. Portola's reversible antiplatelet compound,PRT060128, appeared safe and well-tolerated in this study andachieved high-level platelet inhibition. Portola presented the data in a poster sess...

Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit

KENILWORTH, N.J., March 12, 2007 /PRNewswire-FirstCall/ --Schering-Plough Corporation announced today that results of thePhase II trial of its novel oral thrombin receptor antagonist (TRA)SCH 530348 will be presented at the 2007 annual Scientific Sessionsof the of Cardiology (ACC.07)/Innovation in Intervention (i2)Summit, March 24-27 in New Orleans. The Phase II trial, referred toas the...

Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success

Huge clinical development program of first-in-class CB1antagonist rimonabant to show benefits beyond weight reduction andavoid image as life-style drug BARCELONA, Spain | March 08, 2007 | The Business Intelligencefirm La Merie S.L. reported today that Sanofi-Aventis’first-in-class CB1 antagonist Acomplia (rimonabant) has at leastfive competitors in clinical stages up to phase...